How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy
How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy
www.nytimes.com How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy
Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.
You're viewing a single thread.
View all comments
10
comments
Take profit out of life-saving drugs.
9 1 ReplyYeah, we already have government research funding a lot of medicine. Hell, the MRNA vaccine was DARPA'S doing.
4 0 Reply
You've viewed 10 comments.
Scroll to top